References
- Bogner C, Peschel C, Decker T. Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach. Leuk Lymphoma 2006; 47: 195–205
- Goy A, Younes A, McLaughlin P, Pro B, Romaguera J E, Hagemeister F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refarctory B cell lymphoma. J Clin Oncol 2005; 23: 667–675
- O'Connor O A, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, et al. Phase II clinical experience with the novel proteasome inhibitor Bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676–684
- Fisher R I, Miller T P, O'Connor O A. Diffuse aggressive lymphoma. V C Broudy, N Berliner, R A Larson, L L Leung. American Society of Hematology Educational Program Book, Washington, DC 2004; 221–236
- Richardson P G, Mitsiades C, Hideshima T, Anderson K C. Proteasome inhibition in the treatment of cancer. Cell Cycle 2005; 4: 290–296
- Goy A, Gilles F. Update on the proteasome inhibitor bertezomib in hematologic malignancies. Clin Lymphoma 2004; 4: 230–237
- Tan C, Waldman T A. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T cell leukemia. Cancer Res 2002; 62: 1083–1086
- Palombella V J, Rando O J, Goldberg A L, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-KB1 precurcor protein and the activation of NF-KB. Cell 1994; 78: 773–785
- Ambrosini G, Adida C, Altieri D C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917–921
- Nakayama K, Kamihira S. Survivin an important determinant for prognosis in adult T-cell leukemia: a novel biomarker in practical Hemato-oncology. Leuk Lymphoma 2002; 43: 2249–2255
- Tracey L, Perez-Rosado A, Artiga M J, Carnacho F I, RodriGuez A, Martinez N, et al. Expression of the NF-KB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J Clin Pathol 2005; 206: 123–134
- Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96: 1921–1925
- Schlette E J, Meleinos L J, Goy A, Lai R, Rasidakis G Z. Survivin expression predicts poorer prognosis in anaplastic large cell lymphoma. J Clin Oncol 2004; 22: 1682–1688
- Doucet J P, Hussain A, Al-Rasheed M, Gaidano G, Gutierrez M I, Magrath I, et al. Differences in the expression of apoptotic proteins in Burkitt's lymphoma cell lines: potential models for screening apoptosis-inducing agents. Leuk Lymphoma 2004; 45: 357–362
- Martinez A, Bellesilo B, Bosch F, Ferrer A, Marce S, Villamor N, et al. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 2004; 164: 501–510